ZIVO Bioscience shifts strategy to preserve capital and unlock shareholder value amid approaching revenue inflection point
ZIVO Bioscience, Inc. has issued a detailed and strategically significant letter to shareholders from its Chairman, President, and Chief Executive Officer, John B. Payne, outlining a pivotal shift in the company’s corporate structure. At the center of the communication is the Board of Directors’ decision to pursue deregistration of the company’s securities with the U.S. Securities and Exchange Commission and to cease public reporting obligations.
This move represents a major inflection point in ZIVO’s corporate journey, signaling a transition away from the traditional public market framework toward a more streamlined, cost-efficient operational model. According to the company’s leadership, the decision has been made after extensive evaluation and is firmly rooted in what they believe to be the best long-term interests of shareholders.
Rationale Behind Deregistration
The letter makes clear that the financial and operational burdens associated with maintaining public company status have become increasingly unsustainable relative to ZIVO’s current stage of development. As a smaller company still in the early phases of revenue generation, ZIVO faces disproportionately high costs tied to regulatory compliance, including legal fees, auditing expenses, financial reporting requirements, insurance premiums, and ongoing investor relations activities.
These obligations, while standard for publicly traded entities, can place significant strain on organizations that have not yet reached scale. In ZIVO’s case, management emphasizes that a substantial portion of its financial resources has been diverted toward maintaining compliance rather than being invested directly into business growth, research, and commercialization efforts.
The company’s leadership argues that this allocation of capital is suboptimal, particularly given the need to accelerate development across its key business segments. By stepping away from public reporting requirements, ZIVO expects to significantly reduce overhead costs, thereby freeing up capital for strategic initiatives that have the potential to generate meaningful returns.
Addressing Shareholder Dilution
Another critical factor influencing the decision is the issue of shareholder dilution. As outlined in the letter, the need to fund ongoing public company expenses has required ZIVO to repeatedly access capital markets. Each financing round, while necessary for sustaining operations, has resulted in the issuance of additional shares, thereby diluting the ownership stakes of existing shareholders.
Management views this cycle as detrimental to long-term shareholder value. By eliminating the need for frequent capital raises tied to compliance costs, the company aims to stabilize its capital structure and protect shareholder equity. The move to a non-reporting status is therefore positioned not only as a cost-saving measure but also as a strategy to halt ongoing dilution and preserve value for current investors.
Positioning for Revenue Growth
The timing of this decision coincides with what ZIVO describes as a critical turning point in its commercial trajectory, particularly within its AgTech segment. The company indicates that it is on the verge of generating meaningful revenue through an established distribution partnership. Commercial activities are already underway, and management anticipates that these efforts will translate into tangible financial results in the near term.
Operating as a non-reporting company is expected to enhance ZIVO’s ability to retain and reinvest this revenue. Instead of allocating incoming funds toward regulatory compliance, the company will be able to channel resources directly into scaling operations, expanding production capacity, and advancing product development.
ZIVO further suggests that the combination of anticipated revenue growth and reduced operating expenses could lead to a significant milestone: achieving positive cash flow for the first time in the company’s history. This development would mark a major step forward in establishing financial sustainability and reducing reliance on external financing.
Progress Across Core Business Segments
Beyond the structural changes, the letter provides a comprehensive update on ZIVO’s underlying business fundamentals, highlighting progress across multiple verticals.
In the Animal Health division, the company reports ongoing engagement with major global players in the sector. These organizations are currently conducting internal due diligence on ZIVO’s proprietary non-antibiotic, immune-modulating technology. This technology, which has demonstrated efficacy in multiple studies, represents a potential alternative to traditional antibiotic-based solutions—a particularly important consideration in light of growing concerns about antimicrobial resistance.
Current activities include production optimization, yield improvement, dose titration, and interference studies. The successful completion of these efforts is expected to pave the way for formal partnership and licensing discussions, which could significantly accelerate commercialization and market adoption.
ZIVO is also actively involved in addressing the global challenge of avian influenza. The company notes that the United States Department of Agriculture has recently allocated funding to various research initiatives, including projects led by University of Georgia. ZIVO’s product is expected to play a role in these studies, underscoring its potential relevance in tackling one of the most pressing issues facing the poultry industry.
Expanding Opportunities in AgTech and Human Nutrition
In addition to animal health, ZIVO is making notable strides in its AgTech and human nutrition segment. The company’s ZIVO LIFE™ microalgae-based ingredient has attracted interest from formulators and product developers around the world. This ingredient, derived from proprietary microalgae strains, is positioned as a sustainable and versatile component for a range of applications.
To meet anticipated demand, ZIVO is actively increasing its production capacity. The company’s distribution partner is expected to play a key role in driving near-term revenue growth, leveraging established channels to bring products to market efficiently. This combination of product innovation, market interest, and distribution capability forms the foundation of ZIVO’s growth strategy in this segment.
Strengthening Governance and Alignment
A notable aspect of the letter is the emphasis on alignment between the company’s leadership and its shareholders. The Board of Directors has taken concrete steps to demonstrate this alignment, including the elimination of board compensation. Additionally, any board members who choose to invest in the company do so at full market price, without preferential terms or incentives.
CEO John B. Payne reinforces this commitment by highlighting his own personal investment in the company. By continuing to allocate his own capital to ZIVO, Payne signals confidence in the company’s direction and its long-term potential. This approach is intended to build trust with shareholders and underscore the leadership team’s dedication to value creation.
A Strategic Reset for Long-Term Value
The decision to deregister and cease public reporting can be viewed as a strategic reset—one that prioritizes operational efficiency, financial discipline, and long-term growth over the visibility and liquidity associated with public markets. While this transition may introduce changes in how shareholders access information and trade their holdings, management believes that the benefits outweigh the drawbacks.
By reducing costs, minimizing dilution, and focusing resources on core business activities, ZIVO aims to create a more sustainable foundation for growth. The company’s leadership is clear in its view that this structure will enable it to better capitalize on emerging opportunities across its key markets.
As ZIVO moves forward with this transition, its success will depend on its ability to execute across multiple fronts: scaling production, securing partnerships, converting commercial interest into revenue, and maintaining momentum in research and development. The company’s progress in these areas will be critical in validating the strategic rationale behind its decision.
At the same time, the broader market context—particularly in sectors such as AgTech, animal health, and sustainable nutrition—presents significant opportunities. With increasing demand for environmentally friendly solutions and alternatives to traditional practices, ZIVO’s technology portfolio is well-positioned to address evolving industry needs.
In conclusion, the letter to shareholders outlines a bold and deliberate shift in ZIVO Bioscience’s approach to growth and value creation. By stepping away from the constraints of public reporting and focusing on operational execution, the company is seeking to align its structure with its strategic ambitions. For shareholders, the message is clear: this decision is intended to preserve capital, reduce dilution, and position the company for a more sustainable and potentially rewarding future.
Source link: https://www.businesswire.com
